TJ DaRenTang announced its semi-annual performance, with a net profit attributable to the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%

According to the Zhitong Finance APP, TJ DaRenTang (600329.SH) disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 2.651 billion yuan, a year-on-year decrease of 33.15%; the net profit attributable to shareholders of the listed company was 1.928 billion yuan, a year-on-year increase of 193.08%; the net profit excluding non-recurring gains and losses was 596 million yuan, a year-on-year decrease of 5.93%; and the basic earnings per share were 2.50 yuan.

In the first half of the year, the company achieved a net profit attributable to shareholders of the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%. This was mainly due to the transfer of 12% equity in Tianjin Sihua Pharmaceutical Co., Ltd. (referred to as "Tianjin Sihua"), resulting in a post-tax net gain of 1.308 billion yuan. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 596 million yuan, a year-on-year decrease of 5.93%. This was mainly because, from the end of last year to the reporting period, the company sold its 25% equity in the joint venture Tianjin Sihua twice, and no longer recognized investment income from the joint venture during this period, while the same period included investment income from the Tianjin Sihua joint venture of 106 million yuan. After excluding the impact of this joint venture investment income, the net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, increased by 12.86% year-on-year